The co-operation means that the three agencies will write joint assessment reports for pharmaceutical products that contain both relative clinical and health economic assessments.
Pharmaceutical companies who have a new, but not yet authorized, medical product are welcome to contact one of the three agencies to start the discussion about a possible joint FINOSE assessment. Companies that chose to participate send in their submission file or equivalent health economic documentation to all three agencies. The company shall also sign the wavier of confidentiality to make it possible for the agencies to share information between them. In lack of defined joint processes, relevant national ones will be followed. After the joint assessment, national decisions or recommendations will be made, following national regulations.
If there is an available joint relative effectiveness assessment report from EUnetHTA, that can be used as ground for a joint health economic analysis between Fimea, NoMA and TLV.